Read More 5 minute read Pharma Industry News InflaRx prepares for key INF904 Phase 2a topline readout in chronic skin inflammation trials Find out how InflaRx’s INF904 topline Phase 2a data could redefine treatment for hidradenitis suppurativa and chronic spontaneous urticaria. bySoujanya RaviNovember 8, 2025